INOVIO PHARMACEUTICALS, INC. for INOVIO PHARMACEUTICALS, INC.
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to COVID-19 research and development, vaccine distribution and manufacturing; Issues related to Oncology; Next Generation COVID-19 vaccines and boosters; Medicare Part B and HPV; Issues related to BARDA/ASPR and manufacturing of COVID-19 vaccines and boosters; Prescription Drug User Fee Act (PDUFA); Medical Device User Fees Amendment (MDUFA IV); ARPA-H Act, H.R 5585; Accelerated Approval Integrity Act of 2022, H.R. 6963; Speeding Therapy Access Today (STAT) Act, H.R. 1730; Prevent Pandemic Act, S. 3799
| Lobbyist | Covered position, as disclosed |
|---|---|
| COOKAB HASHEMI | — |
Budget/Appropriations BUD
FY 2023 appropriations - LHHS, AG/FDA, State, Foreign Ops
| Lobbyist | Covered position, as disclosed |
|---|---|
| COOKAB HASHEMI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.